Multiple Sclerosis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For the Ublituximab (treatment) group:

• You are between 18 and 65 years old
• You have been diagnosed with relapsing MS (including relapsing-remitting MS or active secondary progressive MS) based on recognised diagnostic guidelines
• Your doctor has recently referred you to start a medication called ublituximab for your MS

For the Comparison group:

• You are between 18 and 65 years old
• You have been diagnosed with relapsing-remitting MS based on recognised diagnostic guidelines
• You are currently on a steady, unchanged MS medication and do not plan to switch treatments within the next year

Who may not be able to join:

For the Ublituximab group:

• You have a known eye condition (such as diabetic eye disease, macular degeneration, or glaucoma) that could interfere with the study's eye tests
• You have received certain MS medications that reduce B-cells (such as rituximab, ocrelizumab, ofatumumab, or ublituximab) within the past 12 months
• You have had a serious or life-threatening reaction to ublituximab or a similar type of medication in the past
• You have an ongoing or serious infection, such as active hepatitis B, tuberculosis, or HIV, that would make this type of treatment unsafe
• You have received a live or weakened-live vaccine within 4 weeks before your first dose of ublituximab

For the Comparison group:

• You have a known eye condition (such as diabetic eye disease, macular degeneration, or glaucoma) that could interfere with the study's eye tests
• You have taken certain MS medications that reduce B-cells (such as rituximab, ocrelizumab, ofatumumab, or ublituximab) in the past 12 months, or you plan to start one within the next year

Important: Always verify eligibility with the trial site directly before applying.